Skip to content
Screener

CorMedix CRMD Q3 2026 earnings

Reported November 12, 2026 · Before market open

Revenue$54.5MBeat by $2.8M
EPS-$0.19Miss by $0.07
Revenue estimate$51.8M
EPS estimate-$0.12
“CorMedix will be entering 2027 with two meaningful potential growth drivers. First, our pending acquisition of the Heron assets adds four commercial products used in institutional settings of care and is expected to be immediately accretive to earnings and free cash flow upon closing. With an anticipated revenue contribution of between $125 million and $150 million for the full-year 2027, we expect the Heron transaction to effectively double the Company's non-DefenCath annual product revenue. Second, the FDA granted Priority Review to the REZZAYO prophylaxis sNDA, with a PDUFA date in the first quarter of 2027. If approved, we plan to commence promotional efforts in the second half of 2027. We continue to execute on our strategy to generate value from DefenCath in the post-TDAPA era as well as deploy our capital in a disciplined manner to drive future growth. With a strong current cash position and access to additional non-dilutive capital from Pharmakon, we believe we are well positioned to integrate Heron, prepare for REZZAYO expanded commercialization, and build a more diversified company.”
Joseph Todisco

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$54.5M-47.7%
Gross profit$30.0M-69.0%
Operating income-$6.6M-113%
Net income-$14.7M-128%
EPS (diluted)-$0.19-115%

Balance sheet

See full
Cash & equivalents$355.2M+618%
Total equity$461.7M+23.4%
Total assets$917.7M+22.2%

Cash flow

See full
Operating cash flow$89.7M+191%
CapEx$1.9M+278%
Free cash flow$87.8M+189%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$426.36M-50.9%
P/E4×—
P/S1×-3.0×

Profitability

See full
Gross margin84.9%-9.4pp
Operating margin38.6%—
Net margin25.8%—
FCF margin74.6%+39.9pp

Returns & leverage

See full
Return on equity25.4%—
Current ratio2.4×+0.5×

Segments

By product

See full
Melinta Portfolio$31.4M—
DefenCath$17.2M—
Grant income$3.3M—
Contract revenue$2.6M-3.2%

FAQ

When did CorMedix report Q3 2026 earnings?
CorMedix (CRMD) reported Q3 2026 earnings on November 12, 2026 before market open.
What were CorMedix's Q3 2026 revenue and EPS?
CorMedix reported revenue of $54.5M and eps of $-0.19 for Q3 2026.
Did CorMedix beat estimates in Q3 2026?
Revenue beat the consensus estimate of $51.8M by $2.8M. EPS missed the consensus estimate of $-0.12 by $0.07.
How did CorMedix's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 47.7% from $104.3M a year earlier.
Where can I find CorMedix's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-117213) and the 10-Q periodic report (0001410098-26-000067) directly on SEC EDGAR. The filing index links above go to sec.gov.